News

Latest news

Hide mandatory notifications of trade

Expiry of subscription period and last day of trading in subscription rights today

(Oslo, Norway, 29 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES

Subscription rights for participation in the Rights Issue can be exercised during the ongoing subscription period, which will expire today, 29 September 2016, at 16:30 CET.

The period for trading in subscription rights (ticker "BIONOR-T") for the Rights Issue will also expire today, 29 September 2016 at 16:30 CET.

Subscription rights that are not used to subscribe for new shares or not sold before the expiry of the subscription period will have no value and will lapse without compensation to the holder.

For more information, please refer to the Prospectus. The Prospectus is, subject to regulatory restrictions in certain jurisdictions, available on the following website: www.sb1markets.no. Hard copies of the Prospectus may be obtained by contacting the Company (telephone: +47 23 01 09 60) or SpareBank 1 Markets (telephone: +47 24 14 74 00).

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com
Jens Krøis, CFO, +45 208 01 668, jk@bionorpharma.com

Link to announcement in pdf